Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype.
Saved in:
| Title: | Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype. |
|---|---|
| Authors: | Mehta J; Johnson & Johnson, Spring House, PA, USA. jmehta8@its.jnj.com., Thompson C; Johnson & Johnson, Spring House, PA, USA., Scheers E; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium., Leclercq L; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium., Jang SB; Yuhan Corporation, Seoul, Republic of Korea., Kim DK; Yuhan Corporation, Seoul, Republic of Korea., Haddish-Berhane N; Johnson & Johnson, Spring House, PA, USA., Hellemans P; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium., Jiao JJ; Johnson & Johnson, Raritan, NJ, USA., Clemens PL; Johnson & Johnson, Spring House, PA, USA. |
| Source: | Clinical drug investigation [Clin Drug Investig] 2025 Dec; Vol. 45 (12), pp. 935-944. Date of Electronic Publication: 2025 Oct 12. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-1918 |
|---|---|
| DOI: | 10.1007/s40261-025-01494-z |
